PIK3CA and breast carcinoma: Upregulation of the PI3K/AKT/mTOR pathway has been associated with decreased benefit from endocrine therapies in breast cancer, and recent studies support mTOR inhibitors as promising agents for overcoming endocrine resistance [4].